Small-scale GMP production of plasmid DNA using a simplified and fully disposable production method.

GMP RNase Small scale plasmid production antibiotic-free gene vectors fully disposable miniplasmids

Journal

Journal of biotechnology
ISSN: 1873-4863
Titre abrégé: J Biotechnol
Pays: Netherlands
ID NLM: 8411927

Informations de publication

Date de publication:
2019
Historique:
received: 30 11 2018
revised: 18 03 2019
accepted: 05 05 2019
entrez: 11 6 2021
pubmed: 1 1 2019
medline: 1 1 2019
Statut: ppublish

Résumé

In the past years, the demand for small batches of clinical grade plasmid DNA has been growing. For that purpose, we designed and qualified a scaled-down Good Manufacturing Practices (GMP) production method, able to produce small batches (1-4 mg) of plasmid. The developed method does not require any complex production equipment and utilizes only disposable production materials, which makes it easy to implement and simplifies line-clearance. We have successfully used this method to produce several small batches of two different plasmids. The produced plasmids, both formulated in an Electroporation Buffer, are mixed and filled into small, single-use, aliquots. Quality control confirmed the robustness of the developed method and a stability study showed that the final formulation is stable for at least two years. The final patient formulation will be subsequently used in a phase I/II clinical trial in which retina cells of patients with Age Related Macular Degeneration, are transfected. The presented production method can be generically used for other plasmid constructs and final formulation designs.

Identifiants

pubmed: 34112376
pii: S2590-1559(19)30004-6
doi: 10.1016/j.btecx.2019.100007
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

100007

Informations de copyright

Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.

Auteurs

Noor A M Bakker (NAM)

Divisions of Immunology, Pharmacy & Clinical Pharmacology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Plesmanslaan 121, 1066 CX, Amsterdam, the Netherlands; Amsterdam Biotherapeutics Unit, Louwesweg 6, 1066 EC, Amsterdam, the Netherlands.

Renate de Boer (R)

Divisions of Immunology, Pharmacy & Clinical Pharmacology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Plesmanslaan 121, 1066 CX, Amsterdam, the Netherlands; Amsterdam Biotherapeutics Unit, Louwesweg 6, 1066 EC, Amsterdam, the Netherlands.

Corinne Marie (C)

CNRS, Unité de Technologies Chimiques et Biologiques pour la Santé (UTCBS), UMR 8258, F-75006, Paris, France; INSERM, UTCBS U 1022, F-75006, Paris, France; Université Paris Descartes, Sorbonne-Paris-Cité, UTCBS, F-75006, Paris, France; Chimie ParisTech, PSL Research University, UTCBS, F-75005, Paris, France.

Daniel Scherman (D)

CNRS, Unité de Technologies Chimiques et Biologiques pour la Santé (UTCBS), UMR 8258, F-75006, Paris, France; INSERM, UTCBS U 1022, F-75006, Paris, France; Université Paris Descartes, Sorbonne-Paris-Cité, UTCBS, F-75006, Paris, France; Chimie ParisTech, PSL Research University, UTCBS, F-75005, Paris, France.

John B A G Haanen (JBAG)

Divisions of Immunology, Pharmacy & Clinical Pharmacology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Plesmanslaan 121, 1066 CX, Amsterdam, the Netherlands; Divisions of Medical Oncology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Plesmanslaan 121, 1066 CX, Amsterdam, the Netherlands.

Jos H Beijnen (JH)

Divisions of Pharmacy & Clinical Pharmacology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Plesmanslaan 121, 1066 CX, Amsterdam, the Netherlands.

Bastiaan Nuijen (B)

Divisions of Pharmacy & Clinical Pharmacology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Plesmanslaan 121, 1066 CX, Amsterdam, the Netherlands.

Joost H van den Berg (JH)

Divisions of Immunology, Pharmacy & Clinical Pharmacology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Plesmanslaan 121, 1066 CX, Amsterdam, the Netherlands; Amsterdam Biotherapeutics Unit, Louwesweg 6, 1066 EC, Amsterdam, the Netherlands. Electronic address: jh.vd.berg@nki.nl.

Classifications MeSH